Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors - ScienceDirect

Category: Scientific Articles

Advanced Prostate Cancer: AUA/SUO Guideline - American Urological Association

Prostate cancer - The Lancet

Cancers, Free Full-Text

Prostate cancer and PARP inhibitors: progress and challenges, Journal of Hematology & Oncology

PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 Studies

Rucaparib vs. Investigator choice - Problems with TRITON-3

Recent Advances in the Management of Metastatic Prostate Cancer

Novel therapies are changing treatment paradigms in metastatic prostate cancer, Journal of Hematology & Oncology

Rucaparib Bests Physician's Choice for BRCA+ mCRPC